

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**This Page Blank (uspto)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C03C 3/097, 1/00, 4/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 91/17965</b> <b>(43) International Publication Date:</b> 28 November 1991 (28.11.91)
<b>(21) International Application Number:</b> PCT/US91/03516 <b>(22) International Filing Date:</b> 17 May 1991 (17.05.91) <b>(30) Priority data:</b> 525,539 18 May 1990 (18.05.90) US <b>(71) Applicant:</b> UNIVERSITY OF FLORIDA [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US). <b>(72) Inventors:</b> HENCH, Larry, L. ; 3948 NW 23rd Circle, Gainesville, FL 32605 (US). CLARK, Arthur, E. ; 4926 NW 53rd Street, Gainesville, FL 32606 (US). LI, Rounan ; 331-4 Univ. Vlg.S, Gainesville, FL 32603 (US). <b>(74) Agents:</b> CESARI AND McKENNA et al.; 30 Rows Wharf, Boston, MA 02110 (US).		<b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> ALKALI-FREE BIOACTIVE SOL-GEL COMPOSITIONS  <b>(57) Abstract</b> <p>Sol-gel processing techniques are used to produce alkali-free bioactive glass compositions based on SiO<sub>2</sub>, CaO and P<sub>2</sub>O<sub>5</sub>. By varying the SiO<sub>2</sub> content, a range of hydroxyapatite production rates can be obtained; conversely, varying the time of exposure to actual or simulated in vivo solutions permits use of a range of allowable proportions of SiO<sub>2</sub>. The sol-gel derived compositions can be chosen to achieve target values for thermal expansion coefficient, elastic modulus and volume electrical resistivity.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

ALKALI-FREE BIOACTIVE  
SOL-GEL COMPOSITIONS

I. Background of the Invention

A. Field of the Invention

The present invention relates to biocompatible glass compositions, and more particularly to alkali-free compositions produced by a sol-gel process.


B. Description of the Prior Art

Bioactivity is a unique property associated with the ability of a synthetic material to bond with living tissue. All materials implanted in vivo elicit a response from the surrounding tissue. Four types of response are possible: (i) if the material is toxic, the tissue dies; (ii) if the material is nontoxic and dissolves, the surrounding tissue replaces it; (iii) if the material is nontoxic and biologically inactive, a fibrous tissue capsule of variable thickness forms; and (iv) if the material is nontoxic and biologically active, an interfacial bond forms. Bioactive materials are those which produce the fourth type of response.


Three key compositional features distinguish bioactive glasses from traditional soda-lime-silica glasses and provide the driving force for bonding with living tissues. Conventional bioactive glasses, which are well-characterized in the art, typically contain less than 60 mole percent  $\text{SiO}_2$ , high  $\text{Na}_2\text{O}$  and  $\text{CaO}$  content (20-25% each), and a high molar ratio of calcium to phosphorus (ranging around five). When such glasses are exposed to water or body fluids, several key reactions occur. The first is cation exchange, wherein interstitial  $\text{Na}^{+1}$

-2-


and  $\text{Ca}^{+2}$  ions from the glass are replaced by protons from solution, forming surface silanol groups and nonstoichiometric hydrogen-bonded complexes:



This cation exchange also increases the hydroxyl concentration of the solution, leading to attack of the fully dense silica glass network to produce additional silanol groups and controlled interfacial dissolution:



As the interfacial pH becomes more alkaline and the concentration of hydrolyzed surface silanol groups increases, the conformational dynamics attending high numbers of proximal silanol groups, combined with the absence of interstitial ions, cause these groups to repolymerize into a silica-rich surface layer:



Another consequence of alkaline pH at the glass-solution interface is crystallization into a mixed hydroxyl-apatite phase of the  $\text{CaO}$  and  $\text{P}_2\text{O}_5$  that were released into solution during the network dissolution of Equation 2. This takes place on the  $\text{SiO}_2$  surface. The hydroxyapatite crystallites nucleate and bond to interfacial metabolites such as mucopolysaccharides, collagen and glycoproteins. It appears that incorporation of organic biological constituents within the growing hydroxyapatite- and  $\text{SiO}_2$ -rich layers triggers bonding to living tissues characteristic of bioactivity.

Currently, bioactive powders are produced by conven-

-3-

tional processing techniques well-known in the art. The various constituents (e.g., reagent-grade  $\text{Na}_2\text{CO}_3$ ,  $\text{CaCO}_3$ ,  $\text{P}_2\text{O}_5$  and  $\text{SiO}_2$ ) are usually mixed in a suitable mixing device such as a rolling mill, and then heated in a platinum crucible to a temperature (generally between 1250 and 1400 degrees Centigrade) sufficient to cause the particles to melt and coalesce. See, e.g., U.S. Patent No. 4,775,646; Ogino, Ohuchi & Hench, Compositional Dependence of the Formation of Calcium Phosphate Films on Bioglass, 14 J. Biomed. Mat. Res. 55, 56 (1980). The use of such high temperatures and specialized equipment results in significant production costs.

Conventional bioactive glasses suffer from other shortcomings in addition to high cost. These compositions tend to require an alkali metal oxide such as  $\text{Na}_2\text{O}$  to serve as a flux or aid in melting or homogenization. However, the presence of alkali metal oxide ions results in a high pH at the interface between the glass and surrounding fluid or tissue; in vivo, this can induce inflammation. Furthermore, the rate of tissue repair, which drives the interfacial tissue-glass bonding promoted by bioactive material, tends to vary within a narrow pH range. If the surrounding environment grows too acidic or alkaline, repair shuts down, and interfacial bonding is defeated. Consequently, high rates of bioactivity (as measured by surface hydroxyapatite accretion) tend to be associated with significant local pH changes due to the release of alkali metal oxide ions, and have heretofore been avoided.

Conventional glasses also tend to be difficult to mix to homogeneity, a criterion that holds great importance for quality control of materials intended for implantation in the body. This is due to the relatively large grain size of the glass precursors, which generally measure approximately 10 to 1000 microns in diameter. It is difficult to obtain "molecular scale" mixing, i.e., homogeneity at the molecular level, using

-4-

ordinary mixing techniques, such as stirring of the relatively viscous silicate melts.

Finally, for reasons discussed in more detail below, current bioactive powders cannot be prepared with a  $\text{SiO}_2$  content greater than 60 mole percent. This limitation imposes a significant constraint on the producer's ability to tailor the material for a particular situation. It can be highly useful, for example, to vary the rate of hydroxyapatite formation, which is dependent upon  $\text{SiO}_2$  content. As discussed above, the rate of metabolic tissue repair determines how quickly bonding between the tissue and a bioactive material can progress. Therefore, compatibility between the bioactive material and the surrounding tissue will be maximized when the material's bioactivity rate -- that is, the speed with which hydroxyapatite is produced -- matches the body's metabolic repair rate. However, an individual's repair rate can vary with age and disease state, among other factors, rendering identification of a single, ideal bioactivity rate impossible.

The  $\text{SiO}_2$  level also determines the thermal expansion coefficient and elastic modulus of the glass. Particularly in the case of porous compositions, the ability to coat the glass onto a strong substrate (e.g., metal) significantly increases the range of clinical applications to which the glass will be amenable. Such coating is most conveniently accomplished when the thermal expansion coefficient of the glass matches that of the substrate, and restrictions on  $\text{SiO}_2$  variation diminish the range of coefficients that may be achieved. Similarly, particular values or ranges for the elastic modulus can also be important in certain clinical applications (such as avoiding stress shielding of the repair of long bones and joints), rendering some glass compositions unsuitable if the  $\text{SiO}_2$  level cannot be adjusted sufficiently.



## II. Description of the Invention

### A. Brief Summary of the Invention

The present invention utilizes sol-gel technology to synthesize bioactive glass powders from the system  $\text{SiO}_2$ -CaO- $\text{P}_2\text{O}_5$ . The production of ceramic and glass materials by the sol-gel process has been known for many years. A "sol" is a dispersion of colloidal particles in a liquid, and the term "gel" connotes an interconnected, rigid network with pores of submicrometer dimensions and polymeric chains whose average length is greater than a micrometer. Basically, the sol-gel process involves mixing of the glass precursors into a sol; casting the mixture in a mold; gelation of the mixture, whereby the colloidal particles link together to become a porous three-dimensional network; aging of the gel to increase its strength; drying the liquid from the interconnected pore network; dehydration or chemical stabilization of the pore network; and densification, to produce structures with ranges of physical properties. See, e.g., Hench & West, The Sol-Gel Process, 90 Chem. Rev. 33 (1990).

All of these steps can generally be carried out at relatively low temperatures, as compared with traditional glassmaking techniques. Using the procedures described hereinbelow, our powders can be prepared from gels by sintering at 600-800 degrees Centigrade without the use of platinum crucibles. Accordingly, these procedures afford cost-effective production.

The sol-gel process also permits use of very small colloidal particles (on the order of one nanometer or less) as glass precursors, thereby ensuring a high degree of homogeneity and purity in the final product.

Our formulations all involve only  $\text{SiO}_2$ , CaO and  $\text{P}_2\text{O}_5$ ; we

-6-

have been able to eliminate the traditional need for sodium or other alkali metal compounds to assist in producing bioactivity. Not only does this reduce the glass from a four-component to a three-component system, but permits higher levels of bioactivity to be achieved without adverse interfacial pH consequences.

Another advantage of alkali-free formulations is increased volume electrical resistivity. While conventional bioglass compositions exhibit volume electrical resistivities of approximately  $10^4$  ohm-centimeters, those associated with the present compositions are approximately  $10^{10}$  ohm-centimeters. This attribute enhances the application of the invention for use as tissue-bonded electrical leads projecting into the neural system, such as cochlear implants for correction of profound deafness. The volume electrical resistivity of our compositions can be modified by altering the proportions of the constituents.

The amount of  $\text{SiO}_2$  present in our formulations can be varied well beyond that associated with ordinary biocompatible glass compositions. This flexibility derives from the ultrastructural characteristics of the compositions of the present invention, which give rise to a large area density of nucleation sites for hydroxyapatite, and thereby permit use of smaller proportional amounts of  $\text{CaO}$  and  $\text{P}_2\text{O}_5$ . We have discovered a relationship between reaction time and hydroxyapatite formation in our compositions that enables achievement of bioactivity for a target  $\text{SiO}_2$  content by varying the duration of preliminary exposure to in-vivo conditions.

#### B. Brief Description of the Drawings

The foregoing discussion will be understood more readily from the following detailed description of the invention, when

-7-

taken in conjunction with the accompanying drawings, in which:

FIG. 1 is a drying schedule for all compositions listed in Table 1;

FIG. 2 is a calcination schedule for all compositions listed in Table 1;

FIG. 3 depicts comparative X-ray diffraction data for the bioactive gel powders listed in Table 1 after heating to 600 degrees Centigrade in accordance with the schedule shown in FIG. 2, and for 45S5 Bioglass<sup>(R)</sup> prepared using standard melting and casting;

FIG. 4A is an FTIR spectrum for 45S5 Bioglass<sup>(R)</sup> powder before reaction in a simulated in-vivo solution;

FIG. 4B is an FTIR spectrum for 45S5 Bioglass<sup>(R)</sup> powder after 20 hours reaction in simulated in-vivo solution;

FIG. 5 depicts FTIR spectra for 45S5 Bioglass<sup>(R)</sup> and 60S Bioglass<sup>(R)</sup>, after 20 hours reaction in simulated in-vivo solution;

FIGS. 6-9 illustrate changes in the diffuse reflectance spectra of the sol-gel derived bioactive powders after one, two, four and eight hours, respectively, of reaction in simulated in-vivo solution; and

FIG. 10 is an FTIR spectrum of the sol-gel derived bioactive powder represented as 86S in Table 1.

### C. Detailed Description of the Invention

#### 1) General Experimental Procedures

-8-

The glasses of the present invention are prepared from an alkoxysilane, preferably tetraethoxysilane ("TEOS"), an alkoxyphosphate, preferably triethylphosphate ("TEP"), and calcium nitrate using sol-gel preparation techniques. TEOS is first combined with water and nitric acid in a glass container, and covered. The amount of water added is critical, and depends on the degree of homogeneity desired, the amount of gelling, aging and drying time considered tolerable, and the importance of being able to form monoliths (which becomes progressively more difficult as the percentage of silica decreases).

We have found that by maintaining the molar ratio of water to TEOS plus TEP (i.e.,  $H_2O/[TEOS + TEP]$ ), hereinafter the "R ratio") between three and 10 (preferably eight), we were able to obtain complete hydrolysis (and therefore a homogeneous sol), reasonable gelation times (1-2 days), reasonable aging and drying times (2-4 days), and were able to prepare monoliths of the higher silica compositions. The range of R ratio facilitates preparation of coatings (at low R ratios), monoliths (at intermediate R ratios) and powders (at high R ratios).

The nitric acid (preferably 2N) is added to accelerate the hydrolysis reaction of TEOS. We employ a nitric acid volume approximately 1/6 that of the volume of water.

The remainder of the processing schedule must be controlled with some precision due to the unequal hydrolysis rates of the metal alkoxides. The components in the glass container (TEOS, nitric acid and water) are mixed, preferably using a magnetic stirring bar at medium speed. Although TEOS and water are initially immiscible, the solution becomes clear after 10-20 minutes.

-9-

After 60 minutes, TEP is added to the stirring solution. The calcium nitrate is added after another 60 minutes of mixing. The solution is then stirred for an additional hour, following which it is retained in a quiescent state for 20 minutes. During this period the material coalesces into a sol, which is thereafter introduced into polystyrene containers for casting. The containers are sealed with tape and placed into an oven for gelation and aging at 60 degrees Centigrade for 54 hours.

The samples are then removed from the aging chamber, placed in a glass container with a loose cover and the container introduced into a drying oven. We employ the drying schedule depicted graphically in FIG. 1 to make dried-gel powders. Although adherence to this schedule is not critical for powdered forms, a drying schedule must be rigidly adhered to in order to produce monoliths. Appropriate adjustment of the drying schedule to accommodate monolith production is well within the purview of one skilled in the art.

The dried gel is placed in a quartz crucible for further calcination heat treatment. The calcination is carried out in a furnace through which is passed a slow flow of nitrogen gas. The purpose of the nitrogen is to avoid the formation and crystallization of carbonate hydroxylapatite during the heat treatment. Our calcination schedule is depicted graphically in FIG. 2.

## 2) Specific Examples and Analysis

Using the foregoing method, we have synthesized the compositions appearing in the following table:

TABLE 1

-10-

Compositions of bioactive gel powders in mole % (in weight %)

Sample	SiO <sub>2</sub>	P <sub>2</sub> O <sub>5</sub>	CaO
49S	50(49)	4(9)	46(42)
54S	55(54)	4(9)	41(37)
58S	60(58)	4(9)	36(33)
63S	65(63)	4(9)	31(28)
68S	70(68)	4(9)	26(23)
72S	75(72)	4(9)	21(19)
77S	80(77)	4(9)	16(14)
81S	85(81)	4(9)	11(10)
86S	90(86)	4(9)	6(5)

Our experiments indicate useful compositional ranges, by weight, of:

SiO<sub>2</sub> -- 44-86%  
CaO -- 4-46%  
P<sub>2</sub>O<sub>5</sub> -- 3-15%

Use of the above processing technique results in amorphous, glassy gel powders that are chemically stable (e.g., they do not dissolve in aqueous solution). When exposed to simulated body fluids, however, these compositions form a bioactive hydroxyapatite layer on their surfaces. It is also possible to produce glass monoliths instead of powders using known, alternative sol-gel fabrication techniques that may be straightforwardly substituted for the processes described herein; see, e.g., U.S. Patent Nos. 4,849,378; 4,851,150; or 4,851,373 (the disclosures of which are hereby incorporated by reference).

-11-

The powders can also be melted and applied as coatings on sturdy substrates, such as metal, or alumina or other structural ceramics (such as silicon carbide, zirconium oxide or carbon-carbon composites). By varying the amount of  $\text{SiO}_2$ , it is possible to substantially match the thermal expansion coefficients of our compositions with those of compatible substrates. The thermal expansion coefficients associated with the compositions of the present invention vary with the ratio of  $\text{SiO}_2$  to  $\text{CaO}$  plus  $\text{P}_2\text{O}_5$  (i.e.,  $\text{SiO}_2/[\text{CaO} + \text{P}_2\text{O}_5]$ ).

Evidence of the amorphous, glassy nature of the gels listed in Table 1 is shown in the corresponding X-ray diffraction spectra of FIG. 3. The spectrum of a standard  $\text{Na}_2\text{O}$ - $\text{CaO}$ - $\text{P}_2\text{O}_5$ - $\text{SiO}_2$  bioactive glass (45S5 Bioglass<sup>(R)</sup>) is shown for comparison. As can be seen from the depicted spectra, the melt-derived glasses show no X-ray diffraction lines, only a very broad peak characteristic of an amorphous solid. The 49S, 54S and 58S samples show a small amount of crystallinity at the main X-ray peak of hydroxyapatite (approximately 32.5 degrees), while all other samples exhibit spectra corresponding to completely amorphous materials.

In order to evaluate the potential bioactivity of the sol-gel powder compositions, each sample was divided evenly by weight into three aliquot portions, and each portion ground using a mortar and pestle into powders of a different particle size: one portion into 25-35 mesh; one portion into 35-45 mesh; and the remaining portion into 45-170 mesh.

The rate of development of the HCA phase on the surface of the glass particles was used as an in-vitro index of bioactivity. The use of this index is based on studies indicating that a minimum rate of hydroxyapatite formation is necessary to achieve bonding with hard tissues. See, e.g., Hench, Bioactive Ceramics, in Bioceramics: Material Characteristics Versus In

-12-

Vivo Behavior (P. Ducheyne & J.E. Lemons, Eds., 1988) (hereinafter "Hench 1988"), at 54-71. Both the glass composition and its microstructure exert an influence on the development and growth of the HCA phase. For example, as the  $\text{SiO}_2$  content of prior-art melt-derived bioactive glasses approaches and exceeds 60 mole percent, the rates of network dissolution, silica repolymerization and hydroxyl-carbonate apatite crystallization are retarded; this results in reduction and eventual elimination of bioactivity. The rate of development of the HCA phase on the surface of glass powders can be followed as a function of time utilizing the well-known Fourier Transform Infrared ("FTIR") analysis. See, e.g., Warren, Clark & Hench, Quality Assurance of Bioglass<sup>(R)</sup> Powders, 23 J. Biomed. Mat. Res. - App. Biomat. 201 (1989).

We obtained FTIR spectra on standard, melt-derived 45S5 Bioglass<sup>(R)</sup> powder samples prior to and after a simulated in-vivo solution for 20 hours. The results are presented in FIGS. 4A and 4B, which depict the FTIR spectra of the powder before and after exposure, respectively. As shown in FIG. 4A, vibrational peaks are observed only for silica, silica plus alkali, and alkaline earth before exposure to the solution. However, after exposure and as illustrated in FIG. 4B, the spectrum reveals a pair of strong hydroxyapatite peaks. The silicon-oxygen-silicon rocking vibration peak at  $475\text{ cm}^{-1}$  is diminished in the sample after reaction and replaced by the oxygen-phosphorous-oxygen bending vibrations of the hydroxyapatite  $\text{PO}_4^{-3}$  groups at  $598\text{ cm}^{-1}$  and  $566\text{ cm}^{-1}$ . Because of the very small penetration depth of the infrared beam (less than 1 micron), it can be assumed that the hydroxyapatite peaks arise from a surface layer formed on the powder. Accordingly, these observations indicate that the glass surface has become bioactive.

As hereinabove noted, bioactivity tends to diminish with



-13-

increasing  $\text{SiO}_2$  content. This is illustrated in FIG. 5, which compares the FTIR spectra of two prior-art melt-derived glasses after reaction in simulated in-vivo solutions at 37 degrees Centigrade, using the same procedure as that described below in connection with sol-gel powders. The 45S5 Bioglass<sup>(R)</sup> composition (45 weight percent  $\text{SiO}_2$ ) forms strong hydroxyapatite peaks after 20 hours. This composition has been observed to be quite bioactive, and bonds both to hard and soft tissues. In contrast, the 60S composition (60 weight percent  $\text{SiO}_2$ ) does not develop a hydroxyapatite layer, even after 20 hours in solution. This composition has been observed to lack bioactive properties; it does not bond to bone or to soft tissues. Both of these standard compositions contain  $\text{Na}_2\text{O}$ .

The sol-gel derived powders of compositions listed in Table 1 were reacted with tris-buffered solution ( $\text{pH} = 7.2 \pm 0.1$ , to simulate body fluids) at 37 degrees Centigrade for various times. The powders were immersed directly into the buffered solution in a Nalgene bottle and agitated in an incubator shaker at 37 degrees Centigrade. This test procedure allowed the reacting solution to surround and react with the powders in a reliable and reproducible fashion. We performed FTIR analyses on the reacted powders using a diffuse reflectance stage between  $1400 \text{ cm}^{-1}$  and  $400 \text{ cm}^{-1}$  wave numbers.

FIGS. 6 through 9 depict the diffuse reflectance spectra of each bioactive powder at the early stages of reaction (one, two, four and eight hours, respectively). The peaks at  $598 \text{ cm}^{-1}$  and  $566 \text{ cm}^{-1}$  represent P-O bending vibrations in  $\text{PO}_4$  tetrahedra; as discussed previously, these peaks characterize a hydroxyapatite crystalline phase and serve as an indicator of bioactivity.

These spectra illustrate the interrelationship between exposure time,  $\text{SiO}_2$  content and bioactivity. As shown in FIG.

-14-

9, development of the P-O peaks is observed within eight hours for sol-gel glasses with a  $\text{SiO}_2$  content up to 75 mole percent. However, if exposure time is increased to seven days, peaks are observed for glasses containing up to 90 mole percent  $\text{SiO}_2$ ; this is illustrated in FIG. 10. Accordingly, variation of preliminary exposure periods facilitates great flexibility in achieving biocompatibility with a wide range of  $\text{SiO}_2$  proportions; conversely, the constituents of our compositions can be varied in proportion to achieve a desired rate of hydroxyapatite formation (and hence bioactivity).

Without being bound to any particular theory or mechanism, we believe that the enhanced compositional range of bioactivity obtainable with the present invention derives from the presence of small pores (approximately 1.2 to 10 nm) and large surface area of the sol-gel derived powders, as shown in the following table:

TABLE 2

Sample	Surface Area ( $\text{m}^2/\text{g}$ )	Total Pore Volume ( $\text{cc/g}$ )	Average Pore Size (angstroms)
49S	203	0.57	57
54S	213	0.53	50
58S	289	0.49	34
63S	320	0.49	27
68S	326	0.41	25
72S	380	0.38	20
77S	431	0.32	15
81S	547	0.37	14
86S	627	0.45	14

-15-

These ultrastructural features give rise to a large area density of nucleation sites for hydroxyapatite crystallites. With this favorable deposition environment, buildup of a hydroxyapatite layer can take place at higher rates and with lower proportional concentrations of CaO and P<sub>2</sub>O<sub>5</sub> than would be necessary for ordinary bioactive glass compositions. Consequently, bioactive glasses can be prepared with relatively large levels of SiO<sub>2</sub> that exhibit relatively small local pH variations in vivo.

Previous investigations of bioactive glass compositions that bond to bone demonstrate that bonding occurs within 10 to 30 days if the surface area developed in simulated test solutions falls within the range of 200-500 m<sup>2</sup>/g; see, e.g., U.S. Patent No. 4,171,544. The compositions of the present invention all exhibit surface areas greater than 200 m<sup>2</sup>/g (although we believe that the surface area can be reduced below this level while still retaining sufficient rates of hydroxyapatite formation). The growth of the hydroxyapatite film with exposure to simulated in-vivo solutions further augments these surface areas.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

-16-

CLAIMS

1. A bioactive composition prepared using a sol-gel process, and consisting essentially of more than 60 but no more than 86 weight percent  $\text{SiO}_2$ , at least 4 but less than 33 weight percent  $\text{CaO}$  and at least 3 but no more than 15 weight percent  $\text{P}_2\text{O}_5$ .
2. The composition of claim 1 wherein the bioactive glass forms a hydroxyapatite layer upon exposure to body fluids.
3. The composition of claim 1, wherein the percentage of  $\text{SiO}_2$  is chosen to produce a target rate of hydroxyapatite formation.
4. The composition of claim 1, wherein the percentage of  $\text{SiO}_2$  is chosen to produce a target thermal expansion coefficient value.
5. The composition of claim 1, wherein the percentage of  $\text{SiO}_2$  is chosen to produce a target value for volume electrical resistivity.
6. The composition of claim 1, wherein the bioactive glass is produced as a powder using a sol-gel process.
7. The composition of claim 1, wherein the bioactive glass is produced as a monolith using a sol-gel process.
8. The composition of claim 1, wherein the bioactive glass is produced as a coating using a sol-gel process.
9. A bioactive glass powder consisting essentially of  $\text{SiO}_2$ ,  $\text{CaO}$  and  $\text{P}_2\text{O}_5$ , prepared using a a sol-gel process, and having pores with a diameter range of from about 1.2 to about 10 nm and a surface area of at least 200  $\text{m}^2/\text{g}$ , wherein the weight percentage of  $\text{SiO}_2$  is more than 60 but no more than 86, the

-17-

weight percentage of CaO is at least 4 but less than 33, and the weight percentage of P<sub>2</sub>O<sub>5</sub> is at least 3 but no more than 15.

10. A method of making a dental or surgical implant comprising forming the device from a bioactive glass composition consisting essentially of SiO<sub>2</sub>, CaO and P<sub>2</sub>O<sub>5</sub>.

11. The method of claim 11 further comprising the step of preparing the bioactive glass composition using a sol-gel process.

12. A method of producing a bioactive glass composition, comprising the steps of:

- a. combining an alkoxysilane and an alkoxyphosphate to produce a sol;
- b. aging and drying the sol to produce a powder; and
- c. subjecting the powder to calcination to produce an amorphous solid.

13. The method of claim 13 wherein the alkoxysilane and alkoxyphosphate are combined in water using an R ratio ranging from 3 to 10.

14. The method of claim 13 wherein the alkoxysilane is TEOS.

15. The method of claim 13 wherein the alkoxyphosphate is TEP.

1/11




FIG. 1

2/11




FIG. 2




FIG. 3



4/11




FIG. 4A

5/11




FIG. 4B

6/11




FIG. 5

7/11




FIG. 6

8/11




FIG. 7

9/11




FIG.. 8

10/11




FIG. 9

11/11





FIG. 10



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C03C 3/097, 1/00, 4/00</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 91/17965</b> <b>(43) International Publication Date:</b> 28 November 1991 (28.11.91)
<b>(21) International Application Number:</b> PCT/US91/03516 <b>(22) International Filing Date:</b> 17 May 1991 (17.05.91) <b>(30) Priority data:</b> 525,539 18 May 1990 (18.05.90) US <b>(71) Applicant:</b> UNIVERSITY OF FLORIDA [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US). <b>(72) Inventors:</b> HENCH, Larry, L. ; 3948 NW 23rd Circle, Gainesville, FL 32605 (US). CLARK, Arthur, E. ; 4926 NW 53rd Street, Gainesville, FL 32606 (US). LI, Rounan ; 331-4 Univ. Vlg.S, Gainesville, FL 32603 (US). <b>(74) Agents:</b> CESARI AND McKENNA et al.; 30 Rowes Wharf, Boston, MA 02110 (US).		<b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European pa- tent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (Euro- pean patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>  <b>(88) Date of publication of the international search report:</b> 9 January 1992 (09.01.92)
<b>(54) Title:</b> ALKALI-FREE BIOACTIVE SOL-GEL COMPOSITIONS   <b>(57) Abstract</b>  Sol-gel processing techniques are used to produce alkali-free bioactive glass compositions based on SiO <sub>2</sub> , CaO and P <sub>2</sub> O <sub>5</sub> . By varying the SiO <sub>2</sub> content, a range of hydroxyapatite production rates can be obtained; conversely, varying the time of exposure to actual or simulated in vivo solutions permits use of a range of allowable proportions of SiO <sub>2</sub> . The sol-gel derived compositions can be chosen to achieve target values for thermal expansion coefficient, elastic modulus and volume electrical resistivity.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 91/03516

**I. CLASSIFICATION OF SUBJECT MATTER** (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C03C3/097; C03C1/00; C03C4/00

**II. FIELDS SEARCHED**Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	C03C

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are included in the Fields Searched<sup>8</sup>**III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>**

Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0 261 593 (LION CORPORATION) 30 March 1988 see page 6, line 41 - line 53; claims see page 10, line 50 - line 55  ---	1-15

<sup>\*</sup> Special categories of cited documents: <sup>10</sup><sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance<sup>"E"</sup> earlier document but published on or after the international filing date<sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means<sup>"T"</sup> document published prior to the international filing date but later than the priority date claimed<sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<sup>"A"</sup> document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

19 NOVEMBER 1991

Date of Mailing of this International Search Report

04 DEC 1991

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

VAN BOMMEL L.

US 9103516  
SA 50511

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 19/11/91

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0261593	30-03-88	JP-A- 63079665	09-04-88
		JP-A- 63079666	09-04-88
		US-A- 4994414	19-02-91
-----			